NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 240 filers reported holding NEKTAR THERAPEUTICS in Q3 2021. The put-call ratio across all filers is 0.30 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $30,560 | -45.9% | 51,311 | -47.7% | 0.00% | 0.0% |
| Q2 2023 | $56,443 | -72.1% | 98,129 | +557.8% | 0.00% | -87.5% |
| Q4 2021 | $202,000 | -24.1% | 14,917 | +0.6% | 0.01% | -38.5% |
| Q3 2021 | $266,000 | +12.2% | 14,832 | +7.3% | 0.01% | +18.2% |
| Q2 2021 | $237,000 | -30.7% | 13,820 | -19.2% | 0.01% | -31.2% |
| Q1 2021 | $342,000 | +66.0% | 17,103 | +41.3% | 0.02% | +45.5% |
| Q4 2020 | $206,000 | -5.9% | 12,100 | +487.1% | 0.01% | -63.3% |
| Q1 2018 | $219,000 | – | 2,061 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 2,000,000 | $67,200,000 | 3.35% |
| First Light Asset Management, LLC | 763,403 | $25,650,000 | 3.33% |
| BRIDGER MANAGEMENT, LLC | 1,238,489 | $41,613,000 | 3.29% |
| Rhenman & Partners Asset Management AB | 734,445 | $24,677,000 | 2.89% |
| BB BIOTECH AG | 2,020,676 | $67,895,000 | 1.71% |
| Gs Investments, Inc. | 54,200 | $1,821,120,000 | 1.43% |
| Artal Group S.A. | 900,000 | $30,240,000 | 1.24% |
| Cormorant Asset Management, LP | 500,000 | $16,800,000 | 1.14% |
| TOBAM | 640,547 | $21,522,000 | 1.09% |
| Bellevue Group AG | 430,026 | $14,449,000 | 0.80% |